BioSpace News Archive

CURE’s Patented and Proprietary OTF Vitamin D Found to be More Effective than Standard Supplementation in Achieving pre- and post-Surgery Vitamin D Sufficiency Necessary to Reduce Immune-Mediated Damage such as Graft Versus Host Disease (GVHD) CCHMC to Seek Formulary approval for CURE’s OTF Vitamin D Supplement in its Hospital Formulary OXNARD, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- CURE Pharmaceutical Holdings (OTC: CURR), a developer and manufacturer of innovative delivery formulations

As the company continues to support its aggressive national growth, Azzur Group announces the appointment of Ray Jaffe to Vice President of Operations, Shared Services.

Increasing adoption of medical aesthetic devices due to rising demand for beauty treatments is driving medical aesthetic devices market revenue growth.

ERYTECH Pharma,a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, provided a business and financial update at the end of March 2022.

Vincerx Pharma, Inc. reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.

Bolt Biotherapeutics, Inc. reported financial results for the first quarter ended March 31, 2022 and provided an update on recent business highlights.

Salarius Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options, reported important corporate events and its financial results for the first quarter ended March 31, 2022.

Rezolute, Inc. announced its financial results for the third quarter of fiscal 2022 ended March 31, 2022.

Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today reported financial results for the first quarter ended March 31, 2022, and provided clinical development and operational highlights.

2seventy bio, Inc., a leading immuno-oncology cell therapy company, reported financial results and recent highlights for the first quarter ended March 31, 2022.